Effect of Cilostazol in Treating Diabetes-associated Microvascular Complications

Overview

Journal Endocrine

Specialty Endocrinology

Date 2017 Mar 16

PMID 28293857

Citations 23

Authors

Nicole J Asal

Karolina A Wojciak

Affiliations

Soon will be listed here.

Abstract

Purpose: Cilostazol (Pletal), a phosphodiesterase-3 inhibitor, was approved in the United States in 1999 to reduce symptoms of intermittent claudication. Cyclic adenosine monophosphate levels increase from inhibition of phosphodiesterase resulting in anti-platelet, anti-inflammatory, and vasodilatory effects. Diabetes mellitus is a chronic disease that causes endothelial and platelet dysfunction leading to both microvascular and macrovascular complications. This mini-review highlights the emerging evidence suggesting benefits of using cilostazol in treating microvascular complications associated with diabetes mellitus.

Methods: A review of literature was conducted using PubMed and Embase databases focusing on cilostazol use in diabetes mellitus.

Results: Cilostazol demonstrated renoprotective effects in patients with diabetic nephropathy by reducing serum soluble adhesion molecule-1 and monocyte chemoattractant protein-1. Cilostazol's anti-inflammatory actions predictably attenuate glomerular damage from increased leukocyte adherence. Additionally, cilostazol delayed renal dysfunction secondary to type 2 diabetes mellitus as albuminuria was reduced most likely resulting from inhibition of nuclear factor kappa-induced inflammatory and endothelial markers. Cilostazol's anti-inflammatory actions in addition to its vasodilatory actions relieved retinal hypoxia and decreased excessive production of retinal blood vessels suggesting benefit in diabetic retinopathy. Cilostazol did not improve neuropathy symptom scores signifying that it may not be as beneficial in patients with diabetic peripheral neuropathy without diabetic nephropathy or diabetic retinopathy.

Conclusions: Cilostazol's pleiotropic effects may be beneficial in patients with type 2 diabetes mellitus and diabetic nephropathy. Additional, larger studies need to be conducted to assess the benefits and risks of using cilostazol as an alternative agent in treating patients with diabetic microvascular complications.

Citing Articles

Benefits of Cilostazol's Effect on Vascular and Neuropathic Complications Caused by Diabetes.

Musial D, Ajita M, Bomfim G Med Sci (Basel). 2025; 13(1.

PMID: 39846696 PMC: 11755643. DOI: 10.3390/medsci13010001.

Pathogenesis, Assessment, and Treatment of Coronary Microcirculation Dysfunction.

Ji B, Liu X Arq Bras Cardiol. 2024; 121(8):e20230767.

PMID: 39230107 PMC: 11495817. DOI: 10.36660/abc.20230767.

The spectrum and systemic associations of microvascular dysfunction in the heart and other organs.

Emfietzoglou M, Terentes-Printzios D, Kotronias R, Marin F, Montalto C, De Maria G Nat Cardiovasc Res. 2024; 1(4):298-311.

PMID: 39196132 DOI: 10.1038/s44161-022-00045-5.

Cilostazol Ameliorates Motor Dysfunction and Schwann Cell Impairment in Streptozotocin-Induced Diabetic Rats.

Chang L, Wu Y, Wang H, Tseng K, Wang Y, Lu Y Int J Mol Sci. 2024; 25(14).

PMID: 39063088 PMC: 11277457. DOI: 10.3390/ijms25147847.

Cilostazol protects against gastric ulcers by regulating PPAR-γ, HO-1, PECAM-1, pErk-1, NF-κB, Bcl-2, and cleaved caspase-3 protein expression.

El-Shitany N, El-Saidy E, El-Naggar M, Sokar S Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(11):9033-9050.

PMID: 38884677 PMC: 11522149. DOI: 10.1007/s00210-024-03176-7.

References

Chiarelli F, Cipollone F, Mohn A, Marini M, Iezzi A, Fazia M . Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care. 2002; 25(10):1829-34. DOI: 10.2337/diacare.25.10.1829. View

Ha H, Lee H . Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol. 2003; 14(8 Suppl 3):S246-9. DOI: 10.1097/01.asn.0000077411.98742.54. View

Tang W, Lin F, Lee C, Kuo F, Hsieh C, Hsiao F . Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine. 2013; 45(2):293-301. DOI: 10.1007/s12020-013-0002-3. View

Li J, Shah A . ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol. 2003; 14(8 Suppl 3):S221-6. DOI: 10.1097/01.asn.0000077406.67663.e7. View

Liu J, Chuang T, Chen J, Lee C, Hsieh C, Lin T . Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products. Endocrine. 2015; 49(3):703-10. PMC: 4512567. DOI: 10.1007/s12020-015-0545-6. View

Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G, Flex A . Peroxisome proliferator-activated receptors and angiogenesis. Nutr Metab Cardiovasc Dis. 2009; 19(11):751-9. DOI: 10.1016/j.numecd.2009.04.011. View

Gao L, Wang F, Wang B, Gong B, Zhang J, Zhang X . Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression. J Pharmacol Exp Ther. 2006; 318(1):53-8. DOI: 10.1124/jpet.106.101444. View

Antonetti D, Barber A, Bronson S, Freeman W, Gardner T, Jefferson L . Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006; 55(9):2401-11. DOI: 10.2337/db05-1635. View

Aoki Y, Shimizu M, Watanabe N . The blood glucose level increased in parallel with the heart rate following cilostazol administration in three diabetic patients. Intern Med. 2014; 53(8):859-63. DOI: 10.2169/internalmedicine.53.1403. View

10.

Baldwin Jr A . The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996; 14:649-83. DOI: 10.1146/annurev.immunol.14.1.649. View

11.

Shakur Y, Holst L, Landstrom T, Movsesian M, Degerman E, Manganiello V . Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol. 2000; 66:241-77. DOI: 10.1016/s0079-6603(00)66031-2. View

12.

Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac R . Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol. 2009; 5(7):397-406. DOI: 10.1038/nrneph.2009.91. View

13.

Hattori Y, Suzuki K, Tomizawa A, Hirama N, Okayasu T, Hattori S . Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc Res. 2008; 81(1):133-9. DOI: 10.1093/cvr/cvn226. View

14.

Jung K, Kim J, Park H, Park C . Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. J Pharmacol Exp Ther. 2013; 345(3):457-63. DOI: 10.1124/jpet.113.203067. View

15.

Schafer A, Bauersachs J . Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol. 2008; 6(1):52-60. DOI: 10.2174/157016108783331295. View

16.

Miller J, Adamis A, Aiello L . Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997; 13(1):37-50. DOI: 10.1002/(sici)1099-0895(199703)13:1<37::aid-dmr174>3.0.co;2-k. View

17.

Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E . Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2013; 9(4):147-57. DOI: 10.1053/jscd.2000.7216. View

18.

Ha H, Yu M, Choi Y, Kitamura M, Lee H . Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol. 2002; 13(4):894-902. DOI: 10.1681/ASN.V134894. View

19.

Huh J, Seok H, Lee B, Kang E, Lee H, Cha B . Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event. Endocrine. 2014; 47(1):138-45. DOI: 10.1007/s12020-013-0120-y. View

20.

Tashiro K, Koyanagi I, Saitoh A, Shimizu A, Shike T, Ishiguro C . Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2002; 16(1):1-4. PMC: 6807737. DOI: 10.1002/jcla.2057. View